182 related articles for article (PubMed ID: 26714660)
1. Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.
Burlando M; Cozzani E; Campisi C; Di Costanzo A; Parodi A
Acta Derm Venereol; 2016 Aug; 96(6):858-9. PubMed ID: 26714660
[No Abstract] [Full Text] [Related]
2. High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab.
Talamonti M; D'Adamio S; Galluccio T; Andreani M; Pastorino R; Egan CG; Bianchi L; Galluzzo M
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e364-e367. PubMed ID: 31066090
[No Abstract] [Full Text] [Related]
3. Interaction between Smoking and HLA-C*06:02 on the Response to Ustekinumab in Psoriasis.
Svedbom A; Nikamo P; Ståhle M
J Invest Dermatol; 2020 Aug; 140(8):1653-1656.e1. PubMed ID: 32014510
[No Abstract] [Full Text] [Related]
4. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
[TBL] [Abstract][Full Text] [Related]
5. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
[No Abstract] [Full Text] [Related]
7. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
[TBL] [Abstract][Full Text] [Related]
8. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.
De Keyser E; Busard CI; Lanssens S; Meuleman L; Hutten BA; Costanzo A; van den Reek JM; Zweegers J; Lambert J; Spuls PI
Ther Drug Monit; 2019 Oct; 41(5):634-639. PubMed ID: 31107404
[TBL] [Abstract][Full Text] [Related]
9. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
10. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
[No Abstract] [Full Text] [Related]
11. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.
Talamonti M; Galluzzo M; Chimenti S; Costanzo A
J Am Acad Dermatol; 2016 Feb; 74(2):374-5. PubMed ID: 26775778
[No Abstract] [Full Text] [Related]
12. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT).
Paganelli A; Ciardo S; Odorici G; Pellacani G; Conti A
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e249-e251. PubMed ID: 27739122
[No Abstract] [Full Text] [Related]
14. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
[TBL] [Abstract][Full Text] [Related]
15. Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.
Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
Mol Diagn Ther; 2018 Dec; 22(6):717-721. PubMed ID: 30076588
[TBL] [Abstract][Full Text] [Related]
16. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
Vergou T; Moustou AE; Antoniou C
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
[No Abstract] [Full Text] [Related]
17. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
18. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
Assefa GT; Kaneko S; Oguro H; Morita E
J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
[No Abstract] [Full Text] [Related]
19. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
20. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
[Next] [New Search]
